Five Myths About the Thai Cannabis Market That Cost Investors Money

Five myths about the Thai cannabis market cost investors money repeatedly, and each sounds plausible enough to act on. They are: that the market collapsed, that it is worth the multi-billion figures in circulation, that foreigners are shut out, that Thailand is poised to export freely, and that recreational use is returning. Each is wrong in a specific, correctable way.

Myth one: the market collapsed

It consolidated. Shops closed, but demand concentrated into survivors. Treating consolidation as collapse leads investors to avoid a market that is actually re-forming into something workable.

Myth two: it is worth billions on the old forecasts

The widely quoted multi-billion-dollar forecasts were built on pre-contraction growth assumptions and do not hold after recriminalization. Sizing decisions to those numbers leads to overpaying. The real figure is smaller and knowable, and it is not the headline.

Myth three: foreigners are shut out

Foreigners are capped at 49 percent of the licensed core, not excluded. Believing the door is closed means missing the legitimate structured routes that do exist. The cap is a design constraint, not a wall.

Myth four: free export is imminent

The export story runs straight into the certification wall. With almost no EU-GMP certification, Thailand cannot freely supply major medical markets. Investing on the assumption of imminent large-scale export ignores the binding constraint.

Myth five: recreational use is coming back

The politics point the other way. There is no sign of a return to recreational legalization, and betting on one is betting against the regulatory direction.